RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
18 Feb, 2022 | 08:47h | UTC
Commentary on Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022